PORTON

A CUSTOMER-CENTRIC, INNOVATIVE, AND RELIABLE CDMO WITH GLOBAL SOLUTIONS

OEB 1 to 5 | Sub-g to Metric-ton Scale | Pre-clinical to Commercial

Small Molecules

Tides

Biologics & Conjugates

PORTON

Enabling the Public's
Early Access to Good Medicines

Linked in

business@portonpharma.com
www.portonpharma.com

About Porton

With over 4700 employees, Porton Pharma Solutions, a global company with R&D and GMP-compliant manufacturing facilities across US, EU and China, provides customer-centric innovative and reliable CDMO solutions for Small Molecules, Tides, Biologics and Conjugates from pre-clinical to commercial.

2017-2024

Transformed into a Global Leading CDMO

Acquired J-STAR Research Inc. (USA), Xiaogan Plant (China), Fengxian (China) GMP Plant, and Building Slovenia GMP Plant (Europe)

2013-2015

Became a Public Company

1st USFDA Inspection Passed and Listed on Shenzhen Stock Exchange

2005-2008

Started CMO

Changshou (China) Site Started in 2006

5
Regulated Markets Approval

20+
Global Sites

4700+
Global Employees

1400+
R&D Chemists

2000+
Total Capacity (m^3)

1000+
Global Customers

3000+
Milestone Projects

$ 522 M
2023 Revenue

Data as of March 31, 2024

Global Presence

New Jersey 1
South Plainfield
R&D and GMP Manufacturing, DS

New Jersey 2
Cranbury
R&D and GMP Manufacturing, HP & DP

Menges, Slovenia
R&D and GMP Manufacturing, DS

Copenhagen, Denmark
Office

Turnhout, Belgium
Office

Root, Switzerland
Office



Chongqing
Headquarters
R&D and GMP Manufacturing
DS, DP

Xiaogan
Manufacturing, RSM

Shanghai
Headquarters
R&D and GMP Manufacturing
HP DS & DP
Biologics and Conjugates

Yichun
GMP Manufacturing, DS

Global Solutions with Capacity in USA, EU and China



Small Molecules CDMO Services

Process Design, Route Scouting, Development and Optimization for APIs and Intermediates

non-GMP and GMP Manufacturing from Pre-clinical to Commercial for APIs and Intermediates

Pre-formulation Research and Process Development & Optimization

Pre-clinical to Commercial Batches GMP Manufacturing for Drug Product

Comprehensive Analytical R&D and Quality Control

IND/NDA Dossier and CMC Solutions

Drug Substance Capacity

Site	Reactor Volume (m^3)	Reactor Volume Range (L)	Number of Reactors	Temperature Range (°C)	Reaction Pressure (Mpa)
Shanghai 3 GMP/HP Fengxian	75.5	200 to 6,300	46	-80 to 200	-0.1 to 5
Chongqing 2 GMP Changshou	834.3	5 to 10,000	323	-80 to 200	-0.1 to 5
Jiangxi GMP Yichun	519	200 to 5,000	197	-70 to 140	-0.1 to 1.6
Hubei non-GMP Xiaogan	565	1,000 to 6,300	118	-100 to 150	-0.1 to 0.6
GMP/HP New Jersey 1&2	1	5 to 100	18	-80 to 200	-0.1 to 0.095
Total	1,994.8	5 to 10,000	702	-100 to 200	-0.1 to 5

Drug Product Capability and Capacity

New Jersey 2 - Cranbury

Solubility Enhancement
- Particle Engineering
- Co-processing

Dosage Form Development
- OSD
- Liquid & Lyo Powder

GMP Clinical Phase I & II Production
- OSD
- Non-sterile Liquid

Chongqing 3 - Beibei

Tablet	Capsule	Injectable	Semisolid
• IR • MR • Double-layer Tablet	• IR • MR • Micro-pellet Filler	• Ampoule • Vials for Powder & Liquid	• Cream • Ointment • Gel Paste • Gel Patch
• 1 B doses • 60 M doses (HP)	• 200 M doses • 60 M doses (HP)	• 55+ M units	• 50+ M tubes

(Maximum Annual Output Capacity)

Tides CDMO Services

Peptides

- Linear Peptides (<50 aa)
- Cyclic Peptides (<50 aa)
- Peptide Modification
- Key RSMs and Intermediates

Oligonucleotides

- ASO, siRNA
- miRNA
- Aptamer
- sgRNA
- Oligo Modifications

Drug Delivery Materials

- Lonizable Lipids / Cationic Lipids
- Polymers for Drug Delivery
- Complex/Conjugate Polysaccharides
- Other Lipids

Early Stage Development Services

Process Development and DS Manufacturing

Formulation Development and DP Manufacturing

Analytical Development and QC

Registration Services

Biologics and Conjugates CDMO Services

Conjugates

- ADC
- AOC
- PDC

Targeting-vehicle

- Antibody
- Peptide
- Small Molecule

Payload

- Cytotoxic Drugs
- Oligonucleotides
- Radionuclide
- Fluorescers

Linker

- Cys (-SH): S-S, Maleimide Group (mc, mcc, etc.)
- Lys (-NH2): Activated Acid (CO-OSu, etc.)
- Short Peptide (VC, GFGG, etc.)

Early Stage Development Services

Process Development and DS Manufacturing

Formulation Development and DP Manufacturing

Analytical Development and QC

Registration Services

Enabling Chemical Technologies

Particle Engineering

- Controlled Particle Formation
  - Crystallization
  - Precipitation (amorphous)
  - DS-DP Co-processing (composite)
- Controlled Post Processing
  - Filtration, Drying, Milling, etc.

Material Science & Engineering

- Solid Form Screen/Selection/Studies
- Characterizations of DS, Excipient, SD-DP Intermediate and DP
- Pre-formulation Evaluation

Process Engineering

- Process Simulation
- Continuous Processing & Process Control
- Reactor and Equipment Selection/Design
- Scale-up / Production De-risking
- Column & Membrane & Other Separations

Reaction Engineering

- Reaction Kinetics, Mechanism/Pathway, Selectivity
- Reaction Thermodynamics
- Reaction Simulation
- Reaction EHS (safety, e-factor, etc.)

Computational Chemistry & Data Science

- Molecular & Thermodynamic Simulations
- ML-based DoE, Statistical DoE
- Other Computation Methodologies

Operational Excellence

Intellectual Property (IP)

- Audited by 8 of Global Top 20 Pharma (100% Success Rate)
- ISO27001 Information Security Certification

Quality System

- One Porton One Quality System Strictly Following ICH Guidelines
- 5 Authorities GMP Inspections
- 800+ GMP Audits of Customer
- GMP Audits by 17 of Top 20 Global Pharma (100% Success Rate)

FDA U.S. FOOD & DRUG ADMINISTRATION · World Health Organization · EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH · Pmda · 国家药品监督管理局 National Medical Products Administration

Environmental Health & Safety (EHS)

- 180+ EHS Audits and Inspections
- 10+ Global Top 20 Pharma EHS Audits

Regulatory Affairs

- 8 APIs Passed PAI and Approved
- 60+ APIs of Successful PPQ
- 15+ On-going NDA Projects

Supply Chain

- Supply Chain Visibility
- Back Integration
- Local for Local Supply

Project Management

- Customer-centric
- Lifecycle Management
- Efficient and Transparent Communication